PEG-MGF

PEG-MGF (Pegylated Mechano Growth Factor) is a modified version of MGF (Mechano Growth Factor) with polyethylene glycol (PEG) molecules attached to extend its biological half-life. While native MGF acts locally with a very short half-life of minutes, PEGylation allows the peptide to circulate systemically and remain active for hours. This modification fundamentally changes MGF's pharmacokinetics from a local autocrine/paracrine factor to a potential systemic anabolic agent. Research indicates PEG-MGF can activate satellite cells in multiple muscle groups when administered systemically, potentially promoting muscle growth and recovery throughout the body. The extended half-life allows for less frequent dosing compared to non-pegylated MGF. Studies suggest applications for muscle hypertrophy, injury recovery, and conditions involving muscle wasting. However, the systemic nature may reduce the specificity of local MGF's targeted muscle repair function. PEG-MGF requires subcutaneous or intramuscular injection and remains popular in research examining IGF-1 splice variant biology.

PEG-MGF has essentially no peer-reviewed clinical literature; native MGF data are mostly in vitro and animal; the pharmacokinetic effects of PEGylation are poorly published; dosing and safety in humans are unknown.

MGF is the mechano-sensitive IGF-1Ec splice variant produced locally in muscle in response to loading and injury. PEGylation (attachment of polyethylene glycol) is intended to prolong the short native half-life. No published human pharmacokinetic data for PEG-MGF.